摘要
BIM是Bcl一2中含BH3碱基亚家族的成员，是一种重要促凋亡调节蛋白。表皮生长因子受体（epidermal growth factor receptor，EGFR）突变的非小细胞肺癌（non-small cell lung cancer，NSCLC）患者对EGFR-酪氨酸激酶抑制剂（tyrosine kinase inhibitors，TKIs）治疗敏感、疗效显著，但无论近期疗效如何，最终患者都不可避免地产生耐药及病情进展。BIM参与许多癌细胞（乳腺癌、肺癌、骨肉瘤、黑色素瘤）凋亡。近年来，有研究发现BIM表达与EGFR突变NSCLC吉非替尼耐药有关。因此，了解BIM与EGFR-TKIs耐药关系有利于临床指导。本文综述了近年来BIM与EGFR突变NSCLC吉非替尼耐药的关系。
BIM,a member of Bcl-2 family, contains a BH3 domain and has pro-apoptotic function. BIM plays an important role in cell apoptosis. Epidermal growth factor receptor （EGFR）-tyrosine kinase inhibitors （TKIs） demonstrate efficacy in non-small cell lung cancer （NSCLC） patients with EGFR mutation. However, patients who initially respond to EGFR-TKIs treatment invariably develop resistance to the drugs and the disease will progress simultaneously. BIM promotes apoptosis of many tumor cells, t7 such as breast cancer, lung cancer, osteosarcoma, and melanoma. Recently, it has been reported that BIM in NSCLC is associated with gefitinib resistance. Therefore, understanding the BIM-associated resistance to EGFR-TKIs will guide the clinic. This review summarizes recently BIM-associated resistance to gefitinib in NSCLC with EGFR mutation.
出处
《国际呼吸杂志》
2016年第11期875-878,共4页
International Journal of Respiration
关键词
BIM
表皮生长因子受体突变
非小细胞肺癌
吉非替尼耐药
BIM
Epidermal growth factor receptor mutation
Non-small cell lung cancer
Gefitinib resistance
